BioInvent appoints head of clinical development
BioInvent appoints head of clinical development Lund, Sweden: BioInvent International AB (SAX:BINV) has appointed Steven Glazer to the new position Vice President Clinical & Regulatory Affairs. Steven Glazer, 56 years and Canadian citizen, will head BioInvents drug development projects, from preclinical safety studies through clinical studies. He becomes a member of the Management group and reports to the CEO. Previously Steven had a similar position in the Danish branch of the US biotech company Maxygen. Steven, who is an MD, has also worked for Novo Nordisk, and a number of pharmaceutical and biotech companies in Denmark and US. He has previous experience in the clinical development of therapeutic antibodies through taking three candidates from preclinical stage to clinical phase. "With his long and extensive experience from taking drug projects through clinical phase to commercial products, Steven will be a key contributor", comments Svein Mathisen, CEO. "That he also has extensive knowledge about antibodies underpins the value he brings to the company." "Our investment in the development of proprietary therapeutic antibodies is considerably strengthened through the appointment of Steven", Svein Mathisen continues. BioInvent has recently chosen the candidate drug for treatment of HIV infection/AIDS to commence toxicology studies followed by clinical trials. The company runs also innovative drug development projects in indications as atherosclerosis, cancer and osteoarthritis. -- THE END -- For more information BioInvent International AB Svein Mathisen Cristina Glad President and CEO Executive Vice President Telephone: +46 (0)46 286 85 67 Telephone: +46 (0)46 286 85 51 Mobile: +46 (0)708 97 82 13 Mobile: +46 (0)708 16 85 70 E-mail: svein.mathisen@bioivent.com E-mail: cristina.glad@bioinvent.com Legal disclaimer This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release. Background information: BioInvent International AB, listed on the O-list of the Stockholm Exchange (Stockholmsbörsen), develops antibody-based drug candidates against diseases where there is a significant unmet medical need. The antibody field is a segment with strong growth in the pharmaceuticals market and is expected to account for a large portion of drug sales in the future. BioInvent is well positioned to become a leading player in this market with its strong and established technology platform that covers the chain, from the n-CoDeR antibody library for fast and efficient selection of human antibodies to production in a facility that is approved for manufacturing biological drugs. BioInvent conducts today innovative proprietary drug projects in disease areas such as AIDS, atherosclerosis, cancer and diseases of the joints. The scope and strength of BioInvent's technology platform is also used by partners in the development of new drugs. BioInvent's partners include ALK Abelló, Antisoma, Celltech, GlaxoSmithKleine, ImmunoGen, Igeneon and XOMA. The Company has 101 employees and operates in the Ideon Research Park in Lund. BioInvent International AB (publ) Co. reg. no. 556537-7263 Visiting address: Sölvegatan 41 Postal address: SE-223 70 Lund, Sweden Tel.: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/05/17/20040517BIT00300/wkr0001.doc http://www.waymaker.net/bitonline/2004/05/17/20040517BIT00300/wkr0002.pdf